2012-09-18 08:04:36 - New Pharmaceuticals market report from Global Markets Direct: "Fungal Infections - Pipeline Review, H2 2012"

Global Markets Direct's, 'Fungal Infections - Pipeline Review, H2 2012', provides an overview of the Fungal Infections therapeutic pipeline. This report provides information on the therapeutic development for Fungal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fungal Infections. 'Fungal Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463890_fungal_infections_pipeline_review_h2_ ..


Note*: Certain sections in the report may be removed or altered based on the availability

and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Fungal Infections.
* A review of the Fungal Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Fungal Infections pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Fungal Infections.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Fungal Infections pipeline depth and focus of Fungal Infections therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Fungal Infections Therapeutic Products under Development, Key Players in Fungal Infections Therapeutics, Fungal Infections Pipeline Overview, Fungal Infections Pipeline, Fungal Infections Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fungal Infections Overview
Therapeutics Development
An Overview of Pipeline Products for Fungal Infections
Fungal Infections Therapeutics under Development by Companies
Fungal Infections Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Fungal Infections Therapeutics - Products under Development by Companies
Fungal Infections Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Fungal Infections Therapeutics Development
Valeant Pharmaceuticals International
BioDelivery Sciences International, Inc.
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
Stiefel Laboratories, Inc.
ACE BioSciences A/S
Vectura Group plc
Ceragenix Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc.
Samyang Corporation
Quinnova Pharmaceuticals, Inc.
Daewoong Pharmaceutical Co., Ltd.
Dr. Reddy's Laboratories Limited
Eisai Co., Ltd.
Pfizer Inc.
Sigma-Tau S.p.A.
Toyama Chemical Co. Ltd
Bayer AG
Helix BioMedix, Inc.
iCo Therapeutics Inc.
Immtech Pharmaceuticals, Inc.
Almirall, S.A.
Lixte Biotechnology Holdings, Inc.
Basilea Pharmaceutica Ltd.
MethylGene Inc
BioDiem Ltd
NexMed, Inc.
NovaBay Pharmaceuticals, Inc.
Nuvo Research Inc.
Cleveland BioLabs, Inc.
Pacgen Biopharmaceuticals Corporation
Pevion Biotech Ltd
Hisamitsu Pharmaceutical Co., Inc.
Choongwae Pharma Corp
PolyMedix, Inc.
Xel Pharmaceuticals, Inc.
Evolva SA
Novexel SA
Novabiotics Ltd
Anacor Pharmaceuticals, Inc.
Topica Pharmaceuticals Inc.
Nitric Biotherapeutics, Inc.
NovaDigm Therapeutics, Inc.
Ferrer Internacional S.A.
NovaLead Pharma Pvt. Ltd.
Sosei Co. Ltd.
NanoBio Corporation
Globeimmune, Inc.
Promius Pharma, LLC
Moberg Derma AB
Lee's Pharmaceutical Holdings Limited
Viamet Pharmaceuticals, Inc.
Laboratorio Teuto Brasileiro
Pacific Beach BioSciences, Inc

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463890&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.